The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the use of Novartis’ Xolair (omalizumab) as an add-on therapy for the treatment of chronic spontaneous ...
US-based BioMarin Pharmaceutical has announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the US Food and Drug Administration (FDA) voted in favor of approval of Vimizim for the treatment of Morquio A ...
The European Commission has approved Regeneron Pharmaceuticals's Eylea (aflibercept) injection for the treatment of visual impairment caused by macular edema secondary to central retinal vein occlusion (CRVO). Eylea is a recombinant ...
Tags: fusion protein, Eylea
TA XBIEX, MALTA, December 16, 2012 /24-7PressRelease/ -- Vegas Partner Lounge, the home to over 10 casinos, donated $18, 000 to charity this November. Their casinos organized a promotion in support of the Movember cause and encouraged ...
Tags: Vegas Partner Lounge, Donates, Charity
Emmaus Medical, a subsidiary of Emmaus Life Sciences, has received European orphan medicinal product designation for Levoglutamide (L-glutamine) for the treatment of sickle cell disease. Emmaus is at present conducting a trial, at over 30 ...
Tags: sickle cell disease, clinical trial, product designation
The Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has recommended Orphan Drug Designation (ODD) for Erytech Pharma's investigational product Enhoxy. The drug, which is used to treat sickle cell ...
Tags: orphan drug designation, Erytech product, debilitating disease
Arno Therapeutics has received orphan-drug designation for AR-42 to treat neurofibromatosis type 2 (NF2) in the Europe. AR-42 is a broad-spectrum deacetylation inhibitor of both histone and non-histone proteins. The orally ...
Tags: Orphan-Drug designation, inhibitor, AR-42, clinical product